BioSpace News Archive

DP Technology, an “AI for Science” new paradigm-driven company, announced the nomination of DPT0218, a novel small molecule targeting Kv1.3, as a preclinical candidate compound for the treatment of various autoimmune diseases, including Inflammatory Bowel Disease and Atopic Dermatitis.

The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase -positive non-small cell lung cancer, have recently been featured in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

Singleron Biotechnologies announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length Transcriptome Library Kit.

EicOsis Human Health announced the next step in its ongoing human clinical trials: the initiation of Phase 1b multiple-ascending dose clinical trial to test the safety of its drug candidate, EC5026.

Vizient, Inc. projects drug price inflation to grow at 3.8% in the latest Pharmacy Market Outlook.

ProSomnus, Inc. announced today that the United States Food and Drug Administration (the “FDA”) has accepted, and is in the process of reviewing, the Company’s premarket notification for its ProSomnus® EVO® precision medical device for the treatment of patients with severe obstructive sleep apnea.

IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure” or the “Company”) today announced the U.S. Food and Drug Administration (“FDA”) has responded affirmatively to the Company’s request for supervisory review (“Appeal”) under 21 CFR 10.75 regarding the FDA’s prior denial of IceCure’s De Novo Classification Request for treating patients with early-stage, low risk breast cancer.

Akebia Therapeutics®, Inc. announced it has closed a loan facility with funds and accounts managed by BlackRock.

bioAffinity Technologies, Inc. provides a summary of recent Company news.

Ichnos Sciences Inc. (Ichnos), a global, fully integrated, clinical-stage biotech company and Glenmark Pharmaceuticals Ltd. (Glenmark), a leading, research-driven, global pharmaceutical company, today announced the launch of their alliance – Ichnos Glenmark Innovation – to accelerate new drug discovery in cancer treatment.